The hematopoietic growth factors in acute leukemia: US perspective Journal Article
| Authors: | Frankfurt, O.; Tallman, M. S. |
| Article Title: | The hematopoietic growth factors in acute leukemia: US perspective |
| Abstract: | The role of myeloid growth factors (GFs) in the management of acute leukemias has been evaluated extensively in multiple clinical trials. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been given prior to, concurrently with, and/or sequentially after the chemotherapy with the goal of reducing the duration of neutropenia and consequently, the incidence and severity of infections, as well as improving the rate of remissions and overall survival (OS). GFs have also been studied as chemotherapy-sensitizing agents, in an effort to recruit dormant myeloid stem cells into the sensitive phase of the cycle. Additionally, GFs, shown to stimulate proliferation and differentiation of leukemia cells in vitro, have been evaluated as monotherapy in patients with acute leukemia. © 2011 Springer Science+Business Media, LLC. |
| Keywords: | signal transduction; cancer survival; antibiotic agent; unclassified drug; acute granulocytic leukemia; overall survival; mortality; neutropenia; review; doxorubicin; placebo; monotherapy; nonhuman; skin toxicity; disease free survival; cytarabine; protein function; cell proliferation; low drug dose; apoptosis; infection; bone marrow suppression; etoposide; gastrointestinal symptom; mucosa inflammation; thrombocytopenia; cyclophosphamide; dexamethasone; vincristine; cell differentiation; acute lymphoblastic leukemia; febrile neutropenia; length of stay; acute leukemia; myelodysplastic syndrome; nonhodgkin lymphoma; minimal residual disease; mitoxantrone; daunorubicin; drug clearance; disease duration; skin disease; romiplostim; pancytopenia; upregulation; idarubicin; drug half life; recombinant granulocyte colony stimulating factor; anthracycline; leukemia relapse; bacterial infection; mycosis; musculoskeletal disease; recombinant granulocyte macrophage colony stimulating factor; gemtuzumab ozogamicin; leukemia remission; akr 501; eltrombopag; maxy 34; palifermin; recombinant colony stimulating factor 1; recombinant growth factor; recombinant interleukin 11; recombinant interleukin 13; recombinant interleukin 3; recombinant interleukin 5; recombinant stem cell factor; repifermin; degranulation; delayed hypersensitivity; mouth disease; neutrophil granule |
| Journal Title: | Cancer Treatment and Research |
| Volume: | 157 |
| ISSN: | 0927-3042 |
| Publisher: | Springer |
| Date Published: | 2011-01-01 |
| Start Page: | 307 |
| End Page: | 337 |
| Language: | English |
| DOI: | 10.1007/978-1-4419-7073-2_18 |
| PROVIDER: | scopus |
| PUBMED: | 21052964 |
| DOI/URL: | |
| Notes: | Chapter 18 in "Hematopoietic Growth Factors in Oncology" (ISBN: 978-1-4419-7072-5) --- "Export Date: 4 March 2011" - "Source: Scopus" |
